Tolmetin

Low folate status contributes to elevated homocysteine, a metabolite that has been associated with endothelial dysfunction, arterial stiffness, and a higher risk of stroke and coronary heart disease. Large observational studies consistently show that individuals with higher homocysteine levels have greater rates of cardiovascular events, and folate intake is one of the key nutritional determinants of homocysteine. Clinically, folic acid supplementation (often combined with vitamins B6 and B12) can lower homocysteine and appears to modestly reduce stroke risk in some populations, making the identification and correction of folate deficiency an important part of broader cardiovascular risk reduction.

Folate deficiency in the periconceptional period significantly increases the risk of neural tube defects (NTDs) such as spina bifida and anencephaly, because adequate folate is required for proper closure of the embryonic neural tube in the first month of pregnancy. Large observational datasets and randomized trials have shown that appropriate folic acid supplementation before conception and in early pregnancy can reduce NTD risk by roughly 50–70% in the general population, with even greater risk reduction in women with a prior NTD‑affected pregnancy. The practical implication is that all women of childbearing potential, not just those actively planning pregnancy, are typically advised to maintain adequate daily folic acid intake so that red‑cell folate stores are sufficient well before conception occurs.

In older adults, low folate status has been associated with a higher risk of mild cognitive impairment (MCI) and faster cognitive decline over time, likely through effects on one‑carbon metabolism and homocysteine. Several longitudinal cohort studies have found that individuals with lower serum or red‑cell folate and higher homocysteine show steeper declines on memory and global cognition tests, and in some cohorts have a significantly higher incidence of MCI or dementia over follow‑up. The clinically important takeaway is that, when folate deficiency is detected and corrected (usually along with ensuring adequate vitamin B12), some patients demonstrate stabilization or modest improvement in cognitive performance, particularly when interventions are combined with aggressive management of vascular risk factors such as hypertension and diabetes.

In some adults, chronic folate deficiency has been linked to neurological manifestations such as peripheral neuropathy, gait disturbance, and subtle to more overt cognitive impairment, especially in older age. Cohort studies have reported that low serum or red cell folate, and elevated homocysteine, correlate with worse performance on memory and executive‑function tests, and may be associated with increased risk of vascular dementia. The encouraging aspect is that, when folate deficiency is identified early and corrected alongside vitamin B12 when needed, some patients experience improvement in neuropathic symptoms and stabilization or modest gains in cognitive performance, particularly when other vascular risk factors are also addressed.

In pregnancy, inadequate folate status not only increases neural tube defect risk but is also associated with maternal megaloblastic anemia, which can worsen fatigue, reduce exercise tolerance, and increase the likelihood of transfusion around delivery. Observational studies have linked low folate and elevated homocysteine with a higher risk of miscarriage, placental complications, and low birth weight, and some data suggest that suboptimal folate status may contribute to certain infertility contexts, particularly when combined with other nutritional or metabolic stressors. The clinical takeaway is that maintaining sufficient folate intake before conception and throughout pregnancy is a key strategy to reduce anemia and support healthier fertility and pregnancy outcomes beyond neural tube defect prevention.

Folate deficiency has been associated with a higher risk of depressive symptoms, irritability, and other mood disturbances, likely through its role in one‑carbon metabolism, monoamine neurotransmitter synthesis, and methylation processes in the brain. Clinical and epidemiologic studies have found that people with low folate or elevated homocysteine are more likely to experience major depression, and lower folate status has been linked to poorer response to certain antidepressant medications. The encouraging clinical point is that, in folate‑deficient individuals, correcting folate status (often with folic acid or methylfolate, and alongside vitamin B12 when indicated) may improve mood symptoms and, in some cases, enhance antidepressant treatment response, especially when combined with comprehensive psychiatric and lifestyle interventions.